Feasibility of InnovaTive Approaches for Personalized Cardiovascular PREVention: Randomized Controlled Pilot Trial and Multidisciplinary Evaluation for National Health Service Implementation
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 120
- 试验地点
- 7
- 主要终点
- Feasibility for the patients
研究概览
简要总结
The goal of the FITPREV (Feasibility of InnovaTive approaches for personalized cardiovascular PREVention: randomized controlled pilot trial and multidisciplinary evaluation for National Health Service implementation) clinical trial is to study the feasibility of innovative approaches( Polygenic Risk Score and health smartwatch) for personalized primary preventive interventions in cardiovascular diseases (CVD). The main questions it aims to answer are:
- Feasibility of a greater study.
- Feasibility of the interventions in a realistic setting, such as the medical office of a General Practitioner.
Participants will be randomized in one of the four parallel arms:
- standard of care;
- genetic testing for cardiovascular genetic risk (through the cardiovascular Polygenic Risk Score or PRS);
- digital intervention with a wearable device and its app;
- digital intervention and genetic testing
The primary outcomes that are going to be evaluated are patient's and General Practitioners' overall judgment of the study and its feasibility.
Secondarily the efficacy of returning Polygenic Risk Score (PRS) results will be assessed. This will happen on two endpoints: i) change in lifestyle pattern; ii) CVD risk profile modification. The postulated hypothesis is that the achievement of these endpoints is more likely in presence of at least one of the aforementioned interventions than among subjects who receive only traditional risk assessment at baseline.
详细描述
This study aims to evaluate the feasibility and secondarily efficacy of disclosing cardiovascular genetic risk-in the setting of a general practitioner's office-in the promotion of healthier lifestyle behaviors.
The enrollment period will last 6 months, with each participant taking part in the study for 12. There are three key time points in the study, T0 or baseline (enrollment phase), T1 or disclosure visit after one month, T2 intermediate visit(after six months) and T3 or final visit at 12 months. At enrollment, participants will be classified into risk categories based on cardiovascular risk using the SCORE-2 or SCORE 2-OP tool. Individuals aged 40-69, without diabetes or congenital hypercolesterolemia, with a SCORE-2 between 2.5% and 10% and a diagnosys of metabolic syndrome according to the American Hearth Association Criteria will be enrolled.
Once enrolled (T0), all participants will sign the informed consent form and undergo a comprehensive assessment, which includes:
- Completing a questionnaire on socioeconomic status, area of residence, and lifestyle, using the Life's Essential 8 tool. The questionnaire will cover smoking status, alcohol consumption, dietary pattern, sleep pattern, and physical activity. Participants will be classified into favorable, intermediate, or unfavorable individual lifestyle patterns according to the Life's Essential 8 score.
- Blood analysis will be performed to evaluate the lipid profile, including total cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides.
At T1, a disclosure visit will be conducted to explain the assigned lifestyle category, share the results of the blood tests, and provide information on the expected interventions based on the assigned group.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 40 Years 至 69 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Age 40-69 years;
- •10 year cardiovascular risk score SCORE2 between 2.5% and 10%.
- •Diagnosis of metabolic syndrome according to the American Heart Association criteria , defined as the presence of three or more of the following:
- •Central or abdominal obesity, measured by waist circumference (greater than 40 inches - 102 cm in men and 35 inches - 89 cm in women).
- •Elevated triglycerides: levels equal to or greater than 150 mg/dL or use of medication for hypertriglyceridemia.
- •Low HDL cholesterol levels (less than 40 mg/dL in men and less than 50 mg/dL in women) or use of cholesterol-lowering medication.
- •Elevated blood pressure: systolic ≥130 mmHg or diastolic ≥85 mmHg, or use of antihypertensive medication.
- •Elevated fasting blood glucose: ≥100 mg/dL or use of glucose-lowering medication.
排除标准
- •Diabetes:
- •Familial hypercholesterolemia;
- •Previous cardiovascular events.
研究组 & 干预措施
No intervention - Standard of Care
Participants will receive traditional lifestyle advices in order to reduce the risk.
Genetic testing - PRS
Arm Description: Participants will receive the information of the genetic cardiovascular risk (PRS) and personalized advices.
干预措施: Polygenic Risk Score (Behavioral)
Experimental: Digital intervention - app and wearable device
Arm Description: Participants will receive an app and a wearable device for the evaluation of various parameters.
干预措施: Digital app and wearable device (Behavioral)
Digital intervention and genetic testing - PRS
Arm Description: Participants will receive both app and wearable device and PRS information
干预措施: Polygenic Risk Score (Behavioral)
Digital intervention and genetic testing - PRS
Arm Description: Participants will receive both app and wearable device and PRS information
干预措施: Digital app and wearable device (Behavioral)
结局指标
主要结局
Feasibility for the patients
时间窗: 1 year
Feasibility will be measured scoring the answer to a short questionnaire compiled at the end of the study(Using one open question, a few yes/no questions and some questions with a Likert 5 scale of agreement).
Feasibility for the General Practitioners
时间窗: 1 year
Feasibility will be measured scoring the answer to a short questionnaire compiled at the end of the study(Using one open question, a few yes/no questions and some questions with a Likert 5 scale of agreement).
次要结局
- Modification of the Lipid Profile(12 months)
- Change in the Lifestyle Category(12 months)
研究者
Roberta Pastorino
Principal Investigator
Catholic University of the Sacred Heart